AUROBINDO PHARMA 2017-18 Annual Report Analysis

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA 2017-18 Annual Report Analysis
Wed, 19 Dec

AUROBINDO PHARMA has announced its results for the year ended March 2018. Let us have a look at the detailed performance review of the company during FY17-18.

AUROBINDO PHARMA Income Statement Analysis

  • Operating income during the year rose 10.4% on a year-on-year (YoY) basis.
  • The company's operating profit increased by 9.8% YoY during the fiscal. Operating profit margins witnessed a fall and stood at 22.9% in FY18 as against 23.0% in FY17.
  • Depreciation charges increased by 30.5% and finance costs increased by 16.5% YoY, respectively.
  • Other income declined by 12.0% YoY.
  • Net profit for the year grew by 5.3% YoY.
  • Net profit margins during the year declined from 15.3% in FY17 to 14.6% in FY18.

AUROBINDO PHARMA Income Statement 2017-18

No. of Mths Year Ending 12 Mar-17* 12 Mar-18* % Change
Net Sales Rs m 149,157 164,666 10.4%
Other income Rs m 1,159 1,020 -12.0%
Total Revenues Rs m 150,316 165,686 10.2%
Gross profit Rs m 34,343 37,718 9.8%
Depreciation Rs m 4,276 5,580 30.5%
Interest Rs m 667 777 16.5%
Profit before tax Rs m 30,558 32,380 6.0%
Tax Rs m 7,597 8,183 7.7%
Profit after tax Rs m 23,012 24,229 5.3%
Gross profit margin % 23.0 22.9
Effective tax rate % 24.9 25.3
Net profit margin % 15.3 14.6
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Company Reports, Regulatory Filings, Equitymaster



AUROBINDO PHARMA Balance Sheet Analysis

  • The company's current liabilities during FY18 stood at Rs 87 billion as compared to Rs 66 billion in FY17, thereby witnessing an increase of 31.4%.
  • Long-term debt stood at Rs 5 billion as compared to Rs 2 billion during FY17, a growth of 148.7%.
  • Current assets rose 32% and stood at Rs 122 billion, while fixed assets rose 29% and stood at Rs 81 billion in FY18.
  • Overall, the total assets and liabilities for FY18 stood at Rs 211 billion as against Rs 162 billion during FY17, thereby witnessing a growth of 30%.

AUROBINDO PHARMA Balance Sheet as on March 2018

No. of Mths Year Ending 12 Mar-17* 12 Mar-18* % Change
Networth Rs m 93,719 116,804 24.6
 
Current Liabilities Rs m 66,056 86,806 31.4
Long-term Debt Rs m 1,814 4,512 148.7
Total Liabilities Rs m 162,494 211,052 29.9
 
Current assets Rs m 92,062 121,878 32.4
Fixed Assets Rs m 62,919 81,037 28.8
Total Assets Rs m 162,494 211,052 29.9
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Company Reports, Regulatory Filings, Equitymaster



AUROBINDO PHARMA Cash Flow Statement Analysis

  • AUROBINDO PHARMA's cash flow from operating activities (CFO) during FY18 stood at Rs 20 billion on a YoY basis.
  • Cash flow from investing activities (CFI) during FY18 stood at Rs -20 billion, an improvement of 9.5% on a YoY basis.
  • Cash flow from financial activities (CFF) during FY18 stood at Rs 9 billion, an improvement of 145% on a YoY basis.
  • Overall, net cash flows for the company during FY18 stood at Rs 9 billion from the Rs -4 billion net cash flows seen during FY17.

AUROBINDO PHARMA Cash Flow Statement 2017-18

Particulars No. of months 12 12 % Change
Year Ending Mar-17 Mar-18
Cash Flow from Operating Activities Rs m 32,786 19,548 -40.4%
Cash Flow from Investing Activities Rs m -17,870 -19,570 -
Cash Flow from Financing Activities Rs m -19,153 8,642 -
Net Cash Flow Rs m -4,239 8,922 -
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Company Reports, Regulatory Filings, Equitymaster



Current Valuations for AUROBINDO PHARMA

  • The trailing twelve-month earnings per share (EPS) of the company stands at Rs 41.4, an improvement from the EPS of Rs 39.3 recorded last year.
  • The price to earnings (P/E) ratio, at the current price of Rs 733.4, stands at 19.6 times its trailing twelve months earnings.
  • The price to book value (P/BV) ratio at current price levels stands at 3.3 times, while the price to sales ratio stands at 2.3 times.
  • The company's price to cash flow (P/CF) ratio stood at 14.4 times its end-of-year operating cash flow earnings.

Per Share Data/Valuations

No. of Mths Year Ending 12 Mar-17* 12 Mar-18*
Sales per share (Unadj.) Rs 254.6 281.1
TTM Earnings per share Rs 39.3 41.4
Diluted earnings per share Rs 39.3 41.4
Price to Cash Flow x 15.8 14.4
TTM P/E ratio x 19.6 19.6
Price / Book Value ratio x 4.7 3.3
Market Cap Rs m 429,655 429,134
Dividends per share (Unadj.) Rs 2.5 2.5
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Company Reports, Regulatory Filings, Equitymaster



Ratio Analysis for AUROBINDO PHARMA

  • Solvency Ratios
  • Current Ratio: The company's current ratio improved and stood at 1.4x during FY18, from 1.4x during FY17. The current ratio measures the company's ability to pay short-term and long-term obligations.

    Interest Coverage Ratio: The company's interest coverage ratio deteriorated and stood at 42.7x during FY18, from 46.8x during FY17. The interest coverage ratio of a company states how easily a company can pay its interest expense on outstanding debt. A higher ratio is preferable.

  • Profitability Ratios
  • Return on Equity (ROE): The ROE for the company declined and down at 20.7% during FY18, from 24.6% during FY18. The ROE measures the ability of a firm to generate profits from its shareholders capital in the company.

    Return on Capital Employed (ROCE): The ROCE for the company declined and down at 27.4% during FY18, from 32.7% during FY17. The ROCE measures the ability of a firm to generate profits from its total capital (shareholder capital plus debt capital) employed in the company.

    Return on Assets (ROA): The ROA of the company declined and down at 11.8% during FY18, from 14.6% during FY17. The ROA measures how efficiently the company uses its assets to generate earnings.

Key Ratio Analysis

No. of Mths Year Ending 12 Mar-17* 12 Mar-18*
Current ratio x 1.4 1.4
Debtors’ Days Days 68 68
Interest coverage x 46.8 42.7
Debt to equity ratio x 0.0 0.0
Return on assets % 14.6 11.8
Return on equity % 24.6 20.7
Return on capital employed % 32.7 27.4
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Company Reports, Regulatory Filings, Equitymaster



To see how AUROBINDO PHARMA has performed over the last 5 years, please visit here.

AUROBINDO PHARMA Share Price Performance

Over the last one year, AUROBINDO PHARMA share price has moved up from Rs 684.6 to Rs 733.4, registering a gain of Rs 48.8 or around 7.1%.

Meanwhile, the S&P BSE HEALTHCARE Index is trading at Rs 13,870.1 (up 0.1%). Over the last one year it has moved down from 14,277.1 to 13,870.1, a loss of 407 points (down 2.9%).

Overall, the S&P BSE SENSEX is up 8.6% over the year.

(To know more, check out historical annual results for AUROBINDO PHARMA and quarterly results for AUROBINDO PHARMA)

Equitymaster requests your view! Post a comment on "AUROBINDO PHARMA 2017-18 Annual Report Analysis". Click here!

  

Related Views on News

AUROBINDO PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 38.6% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 38.6% YoY). Sales on the other hand came in at Rs 54 bn (up 28.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 10.9% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 10.9% YoY). Sales on the other hand came in at Rs 53 bn (up 30.7% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Finally, Is the Share Price of Yes Bank Ready for a Rebound?(The 5 Minute Wrapup)

Oct 7, 2019

Here's what every individual investor must know about Yes Bank...

Rebound Riches Could be Yours With These Stocks(Profit Hunter)

Oct 4, 2019

The secret to multibagger is not big businesses, but great managements... Here's how to find them to make the most of once in a decade rebound opportunity.

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

5 Smart Money Stocks to Profit from the Market Rebound(The 5 Minute Wrapup)

Oct 11, 2019

Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA 5-YR ANALYSIS

COMPARE AUROBINDO PHARMA WITH

MARKET STATS